Angiotensin-II drives changes in microglia-vascular interactions in rats with heart failure

Insights

Heart failure triggers neuroinflammation by increasing microglia near brain blood vessels. Blocking Angiotensin II AT1a receptors normalizes this interaction, offering a potential treatment for heart failure-related cognitive issues.

Area of Science:

  • Neuroscience
  • Cardiovascular Science
  • Immunology

Background:

  • Microglial activation and pro-inflammatory cytokine release in the central nervous system are linked to heart failure (HF) complications.
  • Existing research highlights Angiotensin II (AngII) signaling in the hippocampus but lacks detail on microglial-vascular interactions in HF.
  • The interplay between microglia and the brain's microvasculature is crucial for blood-brain barrier integrity and cerebral blood flow.

Conclusions:

  • Heart failure alters the brain's microglial-vascular interface, characterized by increased vessel-associated microglia.
  • Angiotensin II AT1a receptor signaling mediates HF-induced microglial recruitment to brain vasculature.
  • Targeting microglial-vascular interactions via AT1aR blockade presents a novel therapeutic approach for neuroinflammation in cardiovascular diseases.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
735
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632